95 results
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:19pm
. Dollars)
Three months ended
March 31
Note
Expenses
Research and development
Consulting, wages and benefits
Directors’ fees
Investor relations … reporting date. If, in the judgment of management, future economic benefits will not flow to the Company, then the Company will assess the recoverable value
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:18pm
and other benefits of any of our product candidates outweigh any safety or other perceived risks;
the FDA’s or the applicable foreign regulatory agency’s … not become or remain profitable. In addition, efforts to educate the medical community and third-party payors on the benefits of our products may
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:17pm
of the Company and (iii) other employee benefits, including stock option agreements under any equity incentive plan of the Company.
(y) Sarbanes Oxley … and the Manager may be subject in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:15pm
2)
Restated
(Note 2)
Expenses
Research and development
Wages and benefits
Consulting
Directors’ fees
Investor relations
Professional fees
General … . If, in the judgment of management, future economic benefits will not flow to the Company, then the Company will assess the recoverable value of the asset
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:13pm
forward-looking statements pertaining to the anticipated effects, benefits and risks of the Consolidation (as defined herein) and the Company’s plans … stakeholders and that the benefits of the Consolidation could include:
Compliance with Minimum Bid Price Requirement for Continued Listing on Nasdaq
424B3
jl4lqj77tt
13 Jun 24
Prospectus supplement
4:12pm
424B3
d5p1jd82
13 Jun 24
Prospectus supplement
4:11pm
424B3
k7ot6em2cnoijjhbx
13 Jun 24
Prospectus supplement
4:10pm
424B3
y857jg19
13 Jun 24
Prospectus supplement
4:10pm
424B3
k4z 2j6zb0
13 Jun 24
Prospectus supplement
4:08pm
6-K
EX-99.1
7lxsie
16 May 24
Condensed Interim Consolidated Financial Statements
6:45pm
6-K
EX-99.2
d3znu1yt 2p
16 May 24
Condensed Interim Consolidated Financial Statements
6:45pm
6-K
EX-10.1
35obc91e3edtrpw9v4
30 Nov 23
XORTX Announces US ATM Offering
4:04pm
424B5
t0htqf7njh8m5wo
29 Nov 23
Prospectus supplement for primary offering
9:57pm
6-K
EX-99.1
7fl1tzavzu
15 Nov 23
Condensed Interim Consolidated Financial Statements
9:30pm
6-K
EX-99.2
4oc9nqo0m3i
15 Nov 23
Condensed Interim Consolidated Financial Statements
9:30pm